Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants

BACKGROUND: ROS1 gene fusion represents a specific subtype of non‐small cell lung cancer (NSCLC). Crizotinib is recommended for ROS1‐positive NSCLC due to its favorable outcome in published clinical trials. However, due to the low incidence of ROS1‐positive NSCLC, there is limited information on rea...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Main Authors: Xu, Haiyan, Zhang, Quan, Liang, Li, Li, Junling, Liu, Zhefeng, Li, Weihua, Yang, Lu, Yang, Guangjian, Xu, Fei, Ying, Jianming, Zhang, Shucai, Wang, Yan
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2020
Assuntos:
Clinical Cancer Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7221311/
https://ncbi.nlm.nih.gov/pubmed/32168429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2984
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares